EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nirsevimab: A Review

Howard Balbi

Pediatric Allergy, Immunology, and Pulmonology · 2024

DOI: 10.1089/ped.2024.0025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Allergy, Immunology, and Pulmonology, 2024. Verfasst von Howard Balbi. Beteiligte Einrichtung: Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Vaccines, Respiratory Tract Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV infections in infants, young children, and elderly persons. In May 2023, the FDA approved 2 vaccines, RSVpreF3 (Arexvy™, GSK) and RSVpreF (Abrysvo™, Pfizer), for adults ages 60 years or older to be given as a single-dose intramuscular injection. July 2023 brought the approval of the first long-acting monoclonal antibody nirsevimab (Beyfortus™, Sanofi and AstraZeneca) for the prevention of RSV disease in infants and young children. Then in August, the FDA approved a vaccine (Abrysvo™, Pfizer) to be given to pregnant women to protect their newborns through passive immunity. This article focuses on nirsevemab that has been recommended by the Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) to be administered for all infants

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanVaccinesRespiratory Tract InfectionsInfantAdultInfant, NewbornHumansChildFemalePregnancyUnited StatesChild, PreschoolAgedAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Stichwörter der Autor:innen

RSVmonoclonal antibodynirsevimabvaccine

Substanzen

nirsevimabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalVaccines

Autor:innen und Institutionen

  • Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA.

Zitieren

APA

Balbi, H. (2024). Nirsevimab: A Review. Pediatric Allergy, Immunology, and Pulmonology. https://doi.org/10.1089/ped.2024.0025

Vancouver

Balbi H. Nirsevimab: A Review. Pediatric Allergy, Immunology, and Pulmonology. 2024. doi:10.1089/ped.2024.0025

BibTeX
@article{Balbi2024,
  author = {Balbi, Howard},
  title = {Nirsevimab: A Review},
  journal = {Pediatric Allergy, Immunology, and Pulmonology},
  year = {2024},
  doi = {10.1089/ped.2024.0025}
}
Kostenlos starten →